Biomarker-driven drug development for allergic diseases and asthma: An FDA public workshop

Area of Science:

• Allergy and Immunology
• Pharmacology and Drug Development
• Biomarker Research

Background:

• The US Food and Drug Administration (FDA) convened a workshop on February 22, 2024, focusing on biomarkers for allergic asthma and food allergy.
• The event brought together regulators, academics, National Institutes of Health (NIH) staff, and industry representatives.
• Key discussions centered on FDA requirements for biomarker adoption as surrogate endpoints in clinical trials.

Purpose of the Study:

• To inform stakeholders about the FDA's criteria for accepting biomarkers in drug development.
• To provide an update on the current progress of various biomarkers for allergic diseases.
• To facilitate a dialogue on regulatory perspectives and ongoing research.

Main Methods:

• A workshop format was utilized, featuring regulatory and investigator presentations.
• Discussions were divided into three sessions: regulatory perspectives, asthma biomarkers, and food allergy biomarkers.
• The report summarizes information presented during the workshop.

Main Results:

• The workshop clarified the FDA's requirements for utilizing biomarkers as surrogate endpoints.
• The current development status of numerous potential biomarkers for allergic asthma and food allergy was presented.
• Regulatory viewpoints from both the FDA and European Union were shared.

Conclusions:

• The workshop highlighted the importance of well-defined biomarkers in advancing drug development for allergic conditions.
• Understanding regulatory pathways is crucial for the successful implementation of biomarkers in clinical trials.
• Continued research and collaboration are essential for validating and adopting new biomarkers for allergic asthma and food allergy treatments.